CHMA - UBS sees 38% upside for Teva in permarket analyst action March, 07 2019 07:39 AM Chiasma Inc. Chiasma (NASDAQ:CHMA) initiated with Overweight rating and $18 (208% upside) price target. Shares up 3% premarket. More news on: Chiasma, Mylan Inc, Teva Pharmaceutical Industries Limited, Healthcare stocks news, Stocks on the move, Read more ...